Abstract. An investigation of disease activity and prevalence of anti-cyclic citrullinated peptide in 200 Saudi Rheumatoid Factor-negative rheumatoid arthritis patients; 164 females and 36 males; with a mean age of 45.14 years (SD = 12.54). 97% were receiving disease modifying therapy; as single (77%) and as combination treatment (20%). Hydroxychloroquine was the most used drug (92 patients). Prevalence of anti-cyclic citrullinated peptide was 61/200 (30.5%). Disease activity scores for 28 joints were low (< 3.2) in 2 (1%) patients, moderate (3.2-5.1) in 38 (19%), and high (> 5.1) in 160 (80%). No significant differences (p > 0.05) between positive and negative anti-cyclic citrullinated peptide patients for Disease Activity Score for 28 Joints, morning stiffness, C-reactive protein, disease duration, and presence of mixed diseases. A substantial number (30.5%) of rheumatoid factor negative patients are anti-cyclic citrullinated peptide positive -therefore anticyclic citrullinated peptide antibodies are a useful diagnostic tool for rheumatoid arthritis in RF-ve rheumatoid arthritis patients from Saudi Arabia. In conclusion, there is no difference in the severity or the treatment of rheumatoid arthritis patients with RF-ve/CCP+ve compared to RFve/CCP-ve patients. Therefore, anti-cyclic citrullinated peptide test is not useful in predicting disease activity and deciding on management in these patients.
Introduction
Rheumatoid arthritis (RA) found in about one percent of the population, making it one of the most common autoimmune diseases in the United States. It can have a serious impact on a patient's quality of life; thus, early intervention is a key to minimizing the damaging effects of the disease [1] .
In 1987, the American College of Rheumatology (ACR) established seven criteria for the diagnosis of rheumatoid arthritis (RA), four of which must be fulfilled for diagnosis. Of which, the only criterion based upon laboratory testing is the detection of abnormal amounts of serum rheumatoid factor (RF) [2] . Testing for RF in the diagnosis of RA has been performed for over fifty years. Unfortunately, the RF test does not yield a high specificity for RA [1] . Nevertheless, RF test became the primary laboratory test used in the diagnosis of RA [3] .
Rheumatoid factor (RF) seropositivity is found in about 50-80% of patients with RA [4] . However, individuals with other autoimmune diseases, with infectious diseases, and even healthy persons, particularly elderly individuals may have RF antibodies in relatively high percentages [4] [5] [6] . This incomplete sensitivity and specificity of RF tests for RA limits their diagnostic usefulness [7] .
Since the discovery of RF, autoantibodies that are more specific have been found in the sera of patients with RA. However, many of these autoantibodies have been either less sensitive or technically inconvenient for routine use [8] . The autoantibodies that showed lower sensitivity for diagnosis of RA than the RF include heavy chain binding protein (BiP) [9, 10] , a nuclear antigen with a molecular weight of 33 kD (RA33 [11] , glucose-6-phosphate isomerase [12] [13] [14] , and anti-filaggrin [15, 16] .
Other autoantibodies are either not very specific or their antigens still to be characterized. The RA33 autoantibody [17] are not very specific for RA, since they are also found in about one-third of systemic lupus erythematosus (SLE) and on mixed connective tissue disease (MCTD) patients [4] . The anti-calpastatin has the same reason as reported by Blass et al. [18] . The p68 autoantibodies were described for RA [19] but the antigen needs further characterization [20] . Interestingly, antibodies to perinuclear granules in the cytoplasm of human buccal cells (antiperinuclear factor (APF)) and antibodies to cytokeratin of stratum corneum of rat esophagus epithelium (antikeratin antibodies (AKA)) were described in 1964 and 1979, respectively. Both were found to be highly specific for RA [15, 21] and were grouped into a family of antibodies called anti-filaggrin autoantibodies (AFA) [22] . Antibodies to Sa antigen were first described using the serum of an RA patient whose name began with 'Sa' [23, 24] . They were also detected in sera of patients with RA and are specific for RA [23] [24] [25] [26] . Researchers discovered that APF, AKA, and anti Sa antibodies target citrullinated proteins [27, 28] .
Initial studies using citrullinated peptide as substrate demonstrated a sensitivity of 76% and a specificity of 96% for RA [27] . Subsequently, a modified assay was developed using cyclic citrullinated peptide (CCP) [29] . The first generation anti-CCP (CCP1) assay proved to be as sensitive as the RF test with a much higher specificity [30] . Its specificity for RA (96%) was better than that previously reported in the RF test for RA (48-92%) [29, [31] [32] [33] [34] .
A second-generation anti-CCP (CCP2) assay was soon developed that employed other citrullinated peptides and yielded a better sensitivity (75%-80%) than the CCP1 assay [30] . Whereas its specificity ranges between 90% and 99% [1, 8, [35] [36] [37] [38] . A correlation of anti-CCP antibodies with radiographic joint damage has also been reported [39] [40] [41] [42] . Anti-CCP assay was also found to have a higher disease predictability [43, 44] and prognostic value [38, 45] than the RF test, while RF appears to be a better marker for patient response to treatment than anti-CCP [46] . Anti-CCP can be detected at an early stage, even before onset of clinical symptoms of RA [44] .
Recently, a third-generation anti-CCP (CCP3) assay was developed to demonstrate a greater sensitivity than that of the CCP2 assay [47, 48] .
Most studies on the diagnostic utility of the anti-CCP test in RA have been done in industrialized countries on subjects of European ancestry [49] , with only a few done in the developing world: Egyptians [50] , Iranians [51] , Thai population [52] , Indians [53] , and black South Africans [54] . These antibodies, to the best of our knowledge, have never been studied in Saudi Arabia. This study investigated the prevalence of anti-CCP in Saudi Rf-negative RA patients seen in a private rheumatology center in Jeddah, Saudi Arabia and examined their relationship to disease activity.
Materials and Methods
Over a period of two years (2/2009 -2/2011), demographic and clinical data were collected at the first visit from RA patients attended to Dr. Dhiya Centre for Rheumatism & Physiotherapy and Acupuncture, Jeddah, Saudi Arabia. All patients met the American College of Rheumatology (ACR) 1978 classification criteria for RA [55] . Demographic data included age, sex and ethnicity. Clinical data included disease duration (dd) by years; disease-modifying anti-rheumatic drugs (DMARDs) use and date of first use. Physician's global assessment (PGA) as 100 mm on scale; a 28-joint counts for tender joints (TJ) and for swelling joints (SJ); early morning stiffness (EMS) in minutes. In addition to laboratory data, which included erythrocyte sedimentation rate (ESR, mm/h), C-reactive protein (CRP), RF, hemoglobin (Hb) and platelets (PLT). For financial reasons, the policy was to order anti-CCP test only for those who were RF negative. Anti-CCP was measured by Electrochemiluminescence (Elecsys analyzer from Roche), which is a CE approved second-generation assay for anti CCP (anti-CCP2), and was considered positive when the concentrations were ≥ 3 IU/ml according to the manufacturer instructions. Hence, IgM rheumatoid factor measured by latex agglutination. Disease activity was assessed using the 28-joint disease activity score (DAS28) [56] , which was calculated according to TJ, SJ, ESR and PGA. Presence of other diseases and family history were also documented.
The collected data were part of standard clinical review, thus ethics approval and informed consent were not obtained.
Statistical Analysis
The data were analyzed using statistical package for social science (SPSS) software version 10.
Results
Demographic, clinical and laboratory features of RA patients are shown in Table 1 . Two hundred RF-negative RA patients who were females 164(82%), males 36(18%); mean age 45.14 years (SD 12.54) were studied. All patients were Saudi who met the American College of Rheumatology 1987 diagnostic criteria for RA. Sixty-three patients (31.5%) had disease duration (dd) ≤ 1 year, while 137 (68.5%) had disease durations >1 year, with a mean of 4.98 years (SD = 5.13). Most (2)), Leflunomide (Arava) (4(1)) and Adalimumab (HUMIRA) (3 as combination); Remicade, Rituximab (MabThera) and Imuran (1 as combination). Combination treatment by DMARDs was used in 40 (20%) patients. Frequency of the patients within the age groups showed an ascending pattern with a peak at 40-49 years, which then descends (Fig 1) . Fifty (25%) RA patients were associated with other diseases ( (Table 6 ). High DAS28 (> 5.1) was present among 80% of the patients with a peak at the age group of 40-49 years (Table 7) . 
Discussion
The present study included consecutive patients who fulfilled at their first visit to the center the ACR classification criteria for RA and who were RF negative; exempted those who, for some reasons, did not bring their anti-CCP results and the non Saudi patients. Two hundred Saudi RF negative RA patients were involved in the study. All patients have been tested for anti-CCP antibodies by using a second-generation assay (CCP2).
How does CCP2 compare with other generations? CCP2 is a CE approved assay with better sensitivity (75%-80%) than the CCP1 assay [30] , whereas its specificity ranges between 90% and 99% [1, 8, [35] [36] [37] [38] . The third-generation anti-CCP (CCP3) assay was found to have the same specificity but greater sensitivity than that of the CCP2 assay [47, 48] . Anti-MCV (autoantibodies against mutated citrullinated vimentin), in some publications, has been described as being somewhat more sensitive than the CCP2 test; however, in such cases the anti-MCV test almost always shows a lower specificity as well [57] . In this cohort of patients, the prevalence of the anti-CCP2 antibodies was 30.5% exhibiting a useful diagnostic tool for RA in RF-negative RA patients from Saudi Arabia.
How do our results compare with the reports from other population groups with RF negative RA? Prevalence of 43.2% was reported by Kroot et al. [58] from Sweden. However, Sihvonen et al. [59] , from Finland, and Kastbom et al. [37] , from Sweden, concluded that 40% of the RFnegative patients were anti-CCP-positive. In black South Africans with early rheumatoid arthritis, the report was 36.4% of the 22 RF negative RA patient were positive for anti-CCP [54] . A percentile of 34.9% in Greek patients, and 34.5% in German patients with RF-negative rheumatoid arthritis were reported by Alexiou et al. [60] and Vallbracht et al. [61] , respectively to have anti-CCP antibodies. Moreover, among a group of Japanese patients, Matsui and coworkers [62] reported that anti-CCP2 was positive in 22% of RF-negative subjects. The authors concluded that anti-CCP2 antibodies are the single most useful test for the overall diagnosis of RA, but that a combination of anti-CCP2 and RF is more useful than either test alone for the diagnosis of very early RA. For the Thai population, anti-CCP2 was positive in 20% of RF-negative subjects [52] . Thus, the authors suggested its usefulness in patients with suspected RA who have had a negative RF test. Anti-CCP1 antibodies (first generation) and anti-CCP2 antibodies (second generation) were found to have different frequencies in various RA patient cohorts [60] . The authors attributed these differences to the presence of different subsets of anti-CCP antibodies directed against different epitopes in citrullinecontaining molecules [27, 34] ; the influence of HLA alleles so that serum anti-CCP antibody levels were higher in RA patients with the shared HLA-DRB1 (SE) epitope, than in RA patients lacking the SE epitope [41] ; the RA treatment (such as anti-TNFα treatment) that has been found to decrease serum anti-CCP antibody levels [63] .
The disease activity DAS28 (5.69) in this cohort fits within the ranges (3.1-6.0) among the 25 countries [64] . Although 160 (80%) patients had high DAS28 scores (> 5.1), but there was no significant differences (p > 0.10) between positive anti-CCP2 and negative anti-CCP2 neither for the disease activity as judged by the DAS28, nor for its constituent measures, morning stiffness, CRP and disease duration. This indicates that anti-CCP2 have limited value in predicting disease activity in these patients. This is in concordance with the findings of Vanichapuntu and coworkers [52] who found no correlation with DAS 28. Also, in Egyptian patients, Abdel-Nasser et al. [50] found no significantly correlations of anti-CCP2 titre with parameters of disease activity, although a correlation was found between anti-CCP2 titre and disease severity (rheumatoid nodules, rheumatoid factor (RF), and radiological damage) and the Health Assessment Questionnaire -Disability Index (HAQ-DI) (p < 0.05). Other investigators found that anti-CCP1-positivity [58] , anti-CCP2-positivity [40] and anti-CCP [37, 60] to be predictors of a severe disease course in RA, as defined either by radiological joint outcome [40, 58] or by swollen joint count and increased CRP concentration [37, 60] . Among the sixty-three early RA patients (dd ≤ 1 year) we found 22/63 (34.92%) with positive anti-CCP antibodies. This proportion makes anti-CCP antibodies test a valuable predictor of the disease in the early RA patient when RF still cannot be detected. In this respect, we are in concordance with Kastbom et al. [37] who concluded that anti-CCP antibody status, in Swedish early RA patients (dd ≤ 1 year), are a valuable predictor of the disease.
Second generation anti-CCP (CCP2) assays yielded a sensitivity of 75%-80% [28] and a specificity of 90%-99% [1, 8, [35] [36] [37] [38] . Recently, in India, Gupta et al. [53] used a second-generation anti-CCP assay (CCP2) and found a 85.71% anti-CCP positivity in the RA patients versus 9.8% in the non-RA group, reflecting a sensitivity of 85% and a specificity of 90.19%. We did not assess the sensitivity and specificity in this baseline cross-sectional analysis. However, assessment of the sensitivity and specificity of anti-CCP assay in Saudi RA patients can be a plan for next study. Presence of mixed diseases was found to lower the prevalence of the anti-CCP positivity, as among the fifty patients that had mixed diseases, only twelve patients (12/50 (24%)) had positive anti-CCP. But this reduction was not statistically significant (p > 0.1). Anti-CCP2 positivity was significantly correlated (p ≤ 0.01) with prednisolone and, methotrexate, indicating a statistically significant distribution of each of these drugs (usage) between positive anti-CCP2 and negative anti-CCP2 groups. However, the prognostic value of the anti-CCP test with respect to response to DMARDs and radiographic progression can be a suggestion for a prospective longitudinal study in Saudi RA patients.
Conclusion and Recommendations
The proportion (30.5%) of RF-negative RA patients, which were anti-CCP positive suggest that anti-CCP2 antibodies had a better diagnostic value than RF for the Saudi RF-negative RA patients, thus, anti-CCP antibodies are a useful diagnostic tool for RA in these patients. This current evidence suggests that anti-CCP antibodies should be measured in RA patients from Saudi Arabia when RF results are negative. However, they have limited value in predicting disease activity in these patients, thus, the treatment decisions cannot be based on the anti-CCP test alone. More studies should be performed in Saudi Arabia, concerning the value of anti-CCP antibodies in RA patients, the sensitivity and specificity of the anti-CCP test in Saudi RA patients, together with its prognostic value with respect to response to DMARDs and radiographic progression.
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